Percheron Therapeutics Started at Buy by Bell Potter >PER.AU

Percheron Therapeutics Started at Buy by Bell Potter >PER.AU

Dow JonesJul 7 18:49 ET

Percheron Therapeutics Started With A$0.14/Share Target Price by Bell Potter>PER.AU

Percheron Therapeutics Started With A$0.14/Share Target Price by Bell Potter>PER.AU

Dow JonesJul 7 18:49 ET

Percheron Therapeutics Names Chief Medical Advisor

Percheron Therapeutics (ASX:PER) appointed Cathryn Clary as chief medical advisor, effective immediately, according to a Monday filing with the Australian bourse. Clary most recently served as consult

MT NewswiresJun 2 19:43 ET

Percheron Therapeutics Completes Enrollment for Phase Two Muscular Dystrophy Trial; Shares Rise 3%

Percheron Therapeutics (ASX:PER) completed the enrollment of 48 non-ambulant boys for its phase 2b trial investigating the use of the ATL1102 medication to treat Duchenne muscular dystrophy, according

MT NewswiresMay 28 23:02 ET

Here's Why We're Watching Percheron Therapeutics' (ASX:PER) Cash Burn Situation

Yahoo FinanceMay 23 20:25 ET

WHO Selects International Nonproprietary Name for Percheron Therapeutics' Drug Candidate ATL1102

Percheron Therapeutics (ASX:PER) said that the World Health Organization chose avicursen as the proposed international nonproprietary name for its investigational drug candidate, ATL1102, according to

MT NewswiresMay 5 23:33 ET